Cadila loses trademark case against Wallace Pharma

Cadila Healthcare Ltd has lost a case for the use of its brandname Mexate against Wallace Pharmaceuticals Pvt Ltd, according to a press release.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money Realasset
moneycontrol.com

Home » News » Business

Jul 21, 2009, 08.50 AM | Source: Business Line

Cadila loses trademark case against Wallace Pharma

Cadila Healthcare Ltd has lost a case for the use of its brandname Mexate against Wallace Pharmaceuticals Pvt Ltd, according to a press release.

Like this story, share it with millions of investors on M3

Cadila loses trademark case against Wallace Pharma

Cadila Healthcare Ltd has lost a case for the use of its brandname Mexate against Wallace Pharmaceuticals Pvt Ltd, according to a press release.

Post Your Comments

Share Cancel

Cadila loses trademark case against Wallace Pharma

Ahmedabad, July 20

Cadila Healthcare Ltd has lost a case for the use of its brandname Mexate against Wallace Pharmaceuticals Pvt Ltd, according to a press release.

Both Cadila and Wallace were the registered owners of the disputed trademark. As per Sec 28(3) and 30(2) of the Trade Marks Act, 1999, one registered owner cannot file a suit for infringement of trademark against another registered owner and hence, the case of infringement became redundant.

The judgment was based on similarities or dissimilarities of the mark, overall get-up, packing material and other factors. Prices of both the products and class of the purchaser were also considered, according to the release.

Wallace sells its product in a cardboard box, whereas Cadila sells it in a foil pack. As the overall getup and packing material were different in both the products, it was declared that there could be no confusion in their marketing.

It is general practice to adopt the mark from the name of the drug. Cadila’s mark is Mexate, an abbreviation of Methotraxate. Wallace’s mark is Mext, an abbreviation of Methotraxate. Therefore, Cadila cannot claim monopoly over the mark which is an abbreviation of a basic drug, said the release.

Taken from Business Line

thehindubusinessline.in

Cadila Health stock price

On May 31, 2016, Cadila Healthcare closed at Rs 336.15, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 454.40 and the 52-week low was Rs 285.02.


The company's trailing 12-month (TTM) EPS was at Rs 19.31 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 17.41. The latest book value of the company is Rs 63.52 per share. At current value, the price-to-book value of the company is 5.29.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Cadila loses trademark case against Wallace Pharma

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login